Picture EBD Group BioPharm America 2021 Digital BPA2021 650x80
Document › Details

ERS Genomics Ltd.. (9/22/20). "Press Release: ERS Genomics Appoints Michael Arciero as Vice-President of Intellectual Property & Commercial Development". Dublin.

Organisations Organisation ERS Genomics Ltd.
  Organisation 2 University of California, San Diego (UCSD)
  Group University of California (System)
Products Product IP services
  Product 2 CRISPR-Cas9 technology
Persons Person Arciero, Michael (ERS Genomics 202009– VP IP + Commercial Development before USC Stevents Center for Innovation)
  Person 2 Rhodes, Eric (ERS Genomics 201606– CEO before Horizon Discovery since 201201 before Sigma-Aldrich + Sangamo Biosciences)

ERS Genomics Limited (“ERS”), which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property (IP) co-owned by Dr. Emmanuelle Charpentier, today announced the appointment of Michael Arciero as Vice-President of Intellectual Property and Commercial Development. In the new role, Michael will oversee the intellectual property portfolio of the company and will become a core member of the Company's global business development team.

Michael has over 15 years of experience in corporate and academic transactions. Most recently he was Director of Technology Commercialization and New Ventures for the USC Stevens Center for Innovation. In this function he led the technology transfer and corporate alliance teams supporting innovation across all disciplines, stemming from over $900M in annual research expenditures. Michael was pivotal in the establishment of new ventures based on intellectual property originating at USC. He has a bachelor’s degree in Biology from the University of California, San Diego, and a Juris Doctorate from the University of San Diego School of Law.

“We are absolutely thrilled to have Michael joining ERS at this stage in our corporate development," said Eric Rhodes, CEO, ERS Genomics. "Michael brings a strong background not only in intellectual property matters, but also in structuring deals with a wide range of companies. He will be a key asset in our global expansion efforts, focused on widespread adoption and use of CRISPR/Cas9 across industries including life sciences, veterinary science, and industrial chemicals.”

“The CRISPR/Cas9 system has already led to important research breakthroughs and we've only scratched the surface of what is possible,” commented Michael Arciero, Vice-President of Intellectual Property and Commercial Development, ERS Genomics. “I'm excited to join ERS and help advance the Company’s mission to increase global commercial access to this revolutionary technology.”

For additional information please visit

For high resolution images please contact Zyme Communications


Katie Odgaard
Zyme Communications
Tel: +44(0)7787 502 947

Record changed: 2020-10-27


Picture EBD Group Global Partnering Four Events One Price 650x80

More documents for ERS Genomics Ltd.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Demy-Colton BioFuture 2021 NYC A October 650x80px

» top